Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026)

Hims & Hers Health (HIMS) reported Convertible Debt of $974.1 million for Q1 2026, little changed sequentially from $972.6 million in Q4 2025.

Hims & Hers Health (HIMS) Convertible Debt (2025 - 2026) Analysis & Trends

Hims & Hers Health (HIMS) has 2 years of Convertible Debt data on file, last reported at $974.1 million in Q1 2026.

For the quarter ending Q1 2026, Convertible Debt changed N/A year-over-year to $974.1 million; the trailing twelve-month figure through Mar 2026 stood at $974.1 million (changed N/A YoY), and the FY2025 full-year result was $972.6 million, changed N/A from the prior year.
Convertible Debt held at $974.1 million in Q1 2026, from $972.6 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $974.1 million in Q1 2026 to a low of $969.5 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Hims & Hers Health	7.48 Bn	6.73 Bn	396.79 Mn

Download Data